Format

Send to

Choose Destination
JAMA. 2018 May 22;319(20):2095-2103. doi: 10.1001/jama.2018.5623.

Effect of More vs Less Frequent Follow-up Testing on Overall and Colorectal Cancer-Specific Mortality in Patients With Stage II or III Colorectal Cancer: The COLOFOL Randomized Clinical Trial.

Author information

1
Abdominal Disease Center, Bispebjerg Hospital and Danish Colorectal Cancer Group, Copenhagen, Denmark.
2
Department of Surgery, Skåne University Hospital, Malmö, Sweden.
3
Department of Surgery, Vâstmanlands Hospital, Västerås, Sweden.
4
Department of Surgery, Aarhus University Hospital, Aarhus, Denmark.
5
Department of Radiology, Aarhus University Hospital, Aarhus, Denmark.
6
Manchester Cancer Research Centre and NIHR Manchester Biomedical Research Centre, the Christie NHS Foundation Trust, Division of Cancer Science, School of Medical Sciences, Faculty of Biology, Medicine, and Health, University of Manchester, Manchester, England.
7
Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.
8
Department of Surgical Science, Uppsala University, Uppsala, Sweden.
9
Department of Health Research and Policy, Stanford University, Stanford, California.

Abstract

Importance:

Intensive follow-up of patients after curative surgery for colorectal cancer is common in clinical practice, but evidence of a survival benefit is limited.

Objective:

To examine overall mortality, colorectal cancer-specific mortality, and colorectal cancer-specific recurrence rates among patients with stage II or III colorectal cancer who were randomized after curative surgery to 2 alternative schedules for follow-up testing with computed tomography and carcinoembryonic antigen.

Design, Setting, and Participants:

Unblinded randomized trial including 2509 patients with stage II or III colorectal cancer treated at 24 centers in Sweden, Denmark, and Uruguay from January 2006 through December 2010 and followed up for 5 years; follow-up ended on December 31, 2015.

Interventions:

Patients were randomized either to follow-up testing with computed tomography of the thorax and abdomen and serum carcinoembryonic antigen at 6, 12, 18, 24, and 36 months after surgery (high-frequency group; n = 1253 patients) or at 12 and 36 months after surgery (low-frequency group; n = 1256 patients).

Main Outcomes and Measures:

The primary outcomes were 5-year overall mortality and colorectal cancer-specific mortality rates. The secondary outcome was the colorectal cancer-specific recurrence rate. Both intention-to-treat and per-protocol analyses were performed.

Results:

Among 2555 patients who were randomized, 2509 were included in the intention-to-treat analysis (mean age, 63.5 years; 1128 women [45%]) and 2365 (94.3%) completed the trial. The 5-year overall patient mortality rate in the high-frequency group was 13.0% (161/1253) compared with 14.1% (174/1256) in the low-frequency group (risk difference, 1.1% [95% CI, -1.6% to 3.8%]; P = .43). The 5-year colorectal cancer-specific mortality rate in the high-frequency group was 10.6% (128/1248) compared with 11.4% (137/1250) in the low-frequency group (risk difference, 0.8% [95% CI, -1.7% to 3.3%]; P = .52). The colorectal cancer-specific recurrence rate was 21.6% (265/1248) in the high-frequency group compared with 19.4% (238/1250) in the low-frequency group (risk difference, 2.2% [95% CI, -1.0% to 5.4%]; P = .15).

Conclusions and Relevance:

Among patients with stage II or III colorectal cancer, follow-up testing with computed tomography and carcinoembryonic antigen more frequently compared with less frequently did not result in a significant rate reduction in 5-year overall mortality or colorectal cancer-specific mortality.

Trial Registration:

clinicaltrials.gov Identifier: NCT00225641.

PMID:
29800179
PMCID:
PMC6583244
DOI:
10.1001/jama.2018.5623
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center